Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 1998

View Archived Issues

Company Profile: Prizm

Novel compounds for allergic/inflammatory disorders discovered at Astra

Oxazolidinone antibacterial agents in development at Zeneca

Byk Gulden claims PDE IV inhibitors for respiratory disorders, dermatoses

AHP discovers centrally active muscarinic agents

New drug therapy option for colonic polyps described

Lilly evaluates cardiovascular effects of Evista in RUTH trial

Gene implicated in ALS identified at Johns Hopkins

FDA advisory committee recommends Taxol for new indications

Elan's Zonegran granted approvable status by FDA

Disappointing preliminary phase III results for lisofylline in BMT

Imutec Pharma begins preclinical development of antitumor agents

NovaDx announces name change for subsidiary

Incyte licenses RNA amplification technology and related patent

Integra Artifical Skin receives CE Mark certification

Phase III trials of Microsponge-entrapped 5-FU begin in the U.S.

Bone resorption test receives reimbursement in Japan

DuPont Merck obtains U.S. rights for anticoagulant

BTG licenses new anxiolytic to Abiogen

Inspire, NeoGenesis form respiratory drugs collaboration

Nonpeptide substance P antagonists reported by Merck & Co.

Antitumor anthracyclines prepared at Pharmacia & Upjohn

Incyte identifies human monocyte chemotactic proprotein

Promising preliminary results obtained with Melacine/Intron A combination in stage IV melanoma

Cytogen halts autologous lymphocyte therapy program

Second patent issues to Zonagen for Vasomax

Combination therapy incorporating troglitazone leads to efficient control of type II diabetes

AIDS vaccine technologies available for licensing from NIH

PIN*POINT method available for licensing from NIH